2012
- 3.29, 2012Others
- Tatsuyoshi Hirano Takes Office as New CEO
- 3.13, 2012R&D
- Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine UMN-0501 (ASP7373)
- 3.6, 2012Manufacturing
- UNIGEN Commences Construction of World-Class Biopharmaceutical Manufacturing Plant
- 2.22, 2012Others
- Protein Sciences Licenses Proprietary expresSF+® Insect Cell Technology to Merck
- 2.14, 2012R&D
- UMN Pharma entered into a licensing agreement with Timo Vesikari, M.D. and Vesna Blazevic, Ph.D. that provides UMN Pharma with exclusive worldwide rights to develop and commercialize a novel norovirus VLP + rotavirus VP6 non-live injectable vaccine.
- 2.7, 2012Finance & Alliance
- Unigen, a UMN Pharma Subsidiary, Selected in First Round of METI's FY 2011 “Subsidy for Domestic Location Promotion Projects”
2011
2010
- 11.9, 2010Finance & Alliance
- UMN Pharma secures exclusive rights from Protein Sciences Corporation to commercialize influenza vaccines in China, Hong Kong, Korea, Singapore and Taiwan
- 11.4, 2010Others
- Protein Sciences Corporation and Emergent BioSolutions, Inc. reach agreement to end all litigation and entanglements between the companies
- 9.30, 2010Finance & Alliance
- Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma’s Cell Culture Based Influenza Vaccine Programs in Japan
- 8.17, 2010Finance & Alliance
- Astellas Pharma Inc. and UMN Pharma Inc. Entered into a Memorandum of Understandings for UMN Pharma's Cell Culture Based Influenza Vaccine Program in Japan
- 4.20, 2010R&D
- UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial
- 4.16, 2010Manufacturing
- API and UMN Pharma Announce Formulation Process Collaboration
- 1.26, 2010Manufacturing
- IHI Corporation and UMN Pharma Announce Manufacturing Collaboration
2009
2008
- 12.22, 2008Others
- Relocation of Tokyo Head Office to Yokohama. Renamed as Yokohama Head Office.
- 8.22, 2008Manufacturing
- UMN Pharma begins preparations for construction of a manufacturing facility for UMN-0501, a pandemic influenza vaccine manufactured using a novel cell culture technique.
- 6.18, 2008R&D
- UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.
- 6.10, 2008R&D
- UMN pandemic influenza vaccine, UMN-0501 designated as orphan drug.
- 4.30, 2008Manufacturing
- UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine.
- 4.10, 2008R&D
- UMN Pharma announced initiation of phase I/II clinical trials for UMN-0501, UMN's pandemic influenza vaccine.
2007
2006
2005
2004
